U.S. FDA approves Ziihera for first-line treatment of advanced gastric cancer

The agency granted approval for zanidatamab-hrii combined with or without tislelizumab and chemotherapy for HER2-positive gastroesophageal adenocarcinoma.

25 Aug, 14:23 — 25 Aug, 14:23

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual2h ago

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - Taiwan News

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma Taiwan News

Read full article →

PERSPECTA

PERSPECTA

U.S. FDA approves Ziihera for first-line treatment of advanced gastric cancer

Sources

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - Taiwan News

Related Stories

New Study Estimates 1 in 4 Former NFL Players Had CTE

Lindsay Clancy Murder Trial Nears Conclusion with Key Witness Testimonies

DRC Ebola Outbreak Sees Over 1,000 Recoveries Amidst Rising Death Toll

Child Critically Injured After Being Struck by Vehicle in Sandefjord, Norway

PERSPECTA